Pricing Log in Create free account
Friday 6 November 2026 Export SYRE’s income statement to Excel — free account

Spyre Therapeutics, Inc.

SYRE Healthcare Biotechnology

Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.

EPS
−624.8%
Free cash flow
−108.8%

Quarter to September 2026, against a year earlier

102.07 5.48 +5.67%
Market cap
$9.2B
P/E
0.0×
Fwd P/E
−4.8×
Dividend yield
—
F-score
3/9
Altman Z
−3.82
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Spyre Therapeutics, Inc. (SYRE) SEC filings, changes and red flags

Red flags

  • Short cash runway

    Spyre Therapeutics, Inc.’s cash and short-term investments cover about 1.2 quarters of its operating cash burn

    10-Q filed · The filing · sec.gov

  • Share dilution

    Shares outstanding rose 22.4% in a year, to 95.0 million

    10-Q filed · The filing · sec.gov

  • Material weakness

    Spyre Therapeutics, Inc.’s 10-K reports a material weakness in internal control over financial reporting

    The material weakness will not be considered remediated until the applicable controls operate for a sufficient period of time, and management has concluded, through testing, that these controls are operating effectively.

    10-K filed · The filing · sec.gov

  • Officer departure

    Spyre Therapeutics, Inc. reported the departure of an officer or director

    8-K filed · The filing · sec.gov

  • Auditor change

    Spyre Therapeutics, Inc. changed auditor from PricewaterhouseCoopers LLP to KPMG LLP

    10-K filed · The filing · sec.gov

Filings

Form Period Filed What it reports Flags
8-K Nov 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2026 P1I2: 19 added · 24 removed · 43 modified
P2I1A: no comparison — low extraction confidence 		Short cash runway Share dilution
8-K Oct 5, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K Sep 8, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 25, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 16 added · 14 removed · 41 modified
P2I1A: no comparison — low extraction confidence
8-K Jun 15, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 29, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 27, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits Officer departure
8-K May 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K Apr 14, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K Apr 13, 2026 2.02 Results of operations and financial condition; 8.01 Other events
8-K Apr 13, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Feb 19, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 110 added · 74 removed · 112 modified
1A: 78 added · 21 removed · 156 modified
7: 18 added · 5 removed · 31 modified 		Auditor change
8-K Jan 12, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Nov 4, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 13, 2025 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K Oct 14, 2025 2.02 Results of operations and financial condition
8-K Aug 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K May 8, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Feb 27, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024 Material weakness
8-K Jan 13, 2025 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 7, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Aug 7, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K May 9, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 29, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 9, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.